The Week Ahead In Biotech: Conferences, Clinical Trial Results And IPOs

Biotech stocks staged a recovery this week after being in the red in the previous two weeks. AbbVie Inc (NYSE: ABBV)'s psoriasis drug Skyrizi received FDA nod. The week also saw the release of strong quarterly earnings by big European pharma gian.....»»

Biotech stocks are on track to extend their losses, bucking the positive broader market sentiment. The week saw Achaogen Inc (NASDAQ: AKAO) filing for Chapter 11 bankruptcy and negative clinical readouts .....»»

Biotech stocks witnessed a slowdown in momentum last week, which was a relatively slow one in terms of news flow. Amgen, Inc. read more.....»»

Biotech stocks saw a resurgence this week, as a post-earnings follow-up rally and company-specific news offered support. read more.....»»

Biotech stocks saw a resurgence this week, as a post-earnings follow-up rally and company-specific news offered support. The iShares NASDAQ Biotechnology Index (ETF) (NASDAQ: IBB) gained about 1.5 percent. The followi.....»»

Here are a few catalysts that can dictate the directional moves of b.....»»

Here are a few catalysts that can dictate the directional moves of biotech stocks in the upcoming week: read more.....»»

Biotech stocks.....»»

Biotech stocks are staging a rebound following the losses incurred in the week ended Oct. 12 amid catalysts that include the third-quarter earnings s.....»»

Biotech stocks saw muted sentiment in the holiday-shortened week ending July 5 af.....»»

Biotech stocks saw muted sentiment in the holiday-shortened week ending July 5 after a strong rebound in the later part of the previous week. Activity was light, although news on clinical trial readouts continued to flow. read more.....»»

Biot.....»»

Biotech stocks ended higher for the second straight week, with the presentations at the American Association of Cancer Research annual meeting taking the spotlight. read more.....»»

Biotech stocks came under pressure last week despite two FDA approvals coming through. read more.....»»

Biotech stocks came under pressure last week despite two FDA approvals coming through. The FDA approved SAGE Therapeutics Inc (NASDAQ:.....»»

The ASCO conference closed Tuesday, although presentations at the conference triggered some huge stocks moves. read more.....»»

Biotech stocks came under pressure earlier in the week, weighed down by negative trial results, mixed FDA verdicts and overall pessimistic broader market sentiment, but recovered in the last two sessions. read more.....»»

The earnings season hasn't panned out well for pharma companies, with Amgen, Inc. (NASDAQ: AMGN), Novartis AG (NYS.....»»

The earnings season hasn't panned out well for pharma companies, with Amgen, Inc. (NASDAQ: AMGN), Novartis AG (NYSE: NVS) and Illumina, Inc. read more.....»»

Biotech stocks came under pressure in the week ending Feb. 22 after advancing in the previous week. The recent week was fairly quiet for the space, with a few earnings reports from small-cap stocks and a handful of conference presentations. read more.....»»